stars 1 stars 2 stars 3

89bio was acquired by Roche in September 2025, making the company a member of the Roche Group. We look forward to advancing our innovative FGF21 analog, pegozafermin, as part of Roche’s Pharmaceuticals Division and continuing our mission to help patients with serious liver and cardiometabolic diseases. Pegozafermin is currently being evaluated in Phase 3 trials for the treatment of Metabolic Dysfunction-Associated Steatohepatitis (MASH) and severe hypertriglyceridemia (SHTG).

89bio Questions

The 89bio annual revenue was $14.8 million in 2026.

Francis Sarena is the COO of 89bio.

79 people are employed at 89bio.

89bio is based in San Francisco, California.

The NAICS codes for 89bio are [325, 3254, 54, 32, 32541, 541].

The SIC codes for 89bio are [873, 28, 87, 283].

Top 89bio Employees

View Similar People
G2 Leader Summer 2026 G2 Best Est ROI Mid-Market Summer 2026 G2 Easiest Admin Mid-Market Summer 2026 G2 Most Implementable Summer 2026 G2 Best Results Mid-Market Summer 2026 G2 Lead Capture Mid-Market Summer 2026 Inc Fastest Growing Private Companies 2026 Inc Best Workplace 2026
g2crowd
G2Crowd Trusted
chromestore
300K+ Plugin Users